Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for ...
Wells Fargo analyst Derek Archila maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight and raises the price target...
KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (C...
Oral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow upEnrollment for re...
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Buy and raises the pr...
William Blair starts Kyverna coverage with Outperform, citing KYV-101's potential as the first FDA-approved CAR-T therapy i...
William Blair analyst Sami Corwin initiates coverage on Kyverna Therapeutics (NASDAQ:KYTX) with a Outperform rating.
Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of ...
